Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 27.
doi: 10.1007/s00259-025-07501-x. Online ahead of print.

68Ga-MY6349 PET/CT-guided TROP2-targeted therapy in mCRPC

Shanshan Wang  1   2   3 , Wei Liu  4   5 , Xudong Ni  1   2   3 , Dingwei Ye  1   2   3 , Shaoli Song  4   5   6 , Yao Zhu  7   8   9
Affiliations

68Ga-MY6349 PET/CT-guided TROP2-targeted therapy in mCRPC

Shanshan Wang et al. Eur J Nucl Med Mol Imaging. .
No abstract available

Keywords: Metastatic castration-resistant prostate cancer; PET/CT imaging; TROP2-targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Fudan University Shanghai Cancer Center. Consent to participate: The written informed consent for publication was obtained from the patients. Consent to publish: The authors affirm that human research participants provided informed consent for publication of the images in Fig. Competing interests: The authors declare no potential conflicts of interest.

References

    1. Yin Y, Fan Y, Ouyang Q, et al. Sacituzumabtirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial. Nat Med. 2025. https://doi.org/10.1038/s41591-025-03630-w . - DOI - PubMed
    1. Sperger JM, Helzer KT, Stahlfeld CN, et al. Expression and therapeutic targeting of TROP-2 in treatment-resistant prostate cancer. Clin Cancer Res. 2023;29(12):2324–35. - PubMed - PMC
    1. Chen H, Zhao L, Pang Y, et al. 68Ga-MY6349 PET/CT imaging to assess Trop2 expression in multiple types of cancer. J Clin Invest. 2024. https://doi.org/10.1172/JCI185408 . - DOI - PubMed - PMC
    1. Tolaney SM, Cardillo TM, Chou C-C, et al. The mode of action and clinical outcomes of sacituzumab govitecan in solid tumors. Clin Cancer Res. 2025;31(8):1390–9. - PubMed - PMC
    1. Bardia A, Jhaveri K, Im S-A, et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2–negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol. 2025;43(3):285–96. - PubMed

LinkOut - more resources